portonadvanced.comCrawled Oct 16, 2026
The page lists brochures on cell engineering services and investigator-initiated clinical trial (IIT) services in China.
The page lists end-to-end ATMP CRO and CDMO services, including cell engineering, CMC services, plasmids, lentivirus, mRNA and LNP, bacterial vectors, exosomes, iPSC-derived cell therapies, and GMP lentivirus.
The company offers lab services to support research needs.
Porton Advanced secures a Class C drug manufacturing license, strengthening its CDMO capabilities and supporting pharmaceutical commercialization.
The page lists publications and whitepapers, including a May 13, 2025 publication on engineering and in vitro selection of an AAV3B variant with high hepatocyte tropism and reduced seroreactivity.
Porton Advanced and Bennu Biotherapeutics (Bennubio) announced a strategic partnership to advance cell and gene therapy R&D pipelines. The partnership aims to accelerate T-cell therapy development for tumors and autoimmune diseases.
Porton Advanced and Sinorda Biomedicine announced a long-term strategic partnership in cell and gene therapy R&D and platform development. Porton Advanced offers an end-to-end gene and cell engineering CDMO platform.
Porton Advanced and Yinjia Biosciences announced a strategic partnership to develop core protein raw materials for cell and gene therapy and test reagent products for quality control and evaluation systems.
Porton Biologics announced a strategic cooperation with KAEDI on May 31, 2021, and will provide CMC services for KAEDI’s CAR-T cell therapies.
The careers page provides an application form for job applicants and contact information for further discussion about a role.
Porton Advanced provides end-to-end CDMO solutions for Advanced Therapy Medicinal Products (ATMPs).
The page covers development, GMP manufacturing, preclinical and clinical work, and global regulatory matters.
The page invites businesses to contact Porton Advanced about ATMP R&D projects suited to their needs and provides a phone number and email address.
The company reports 24 IND approvals: 17 from NMPA, 6 from FDA, and 1 from MedSafe.
